Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative

Archives of General Psychiatry

Volumn 68, Issue 9, 2011, Pages 961-969

  Gomar, Jesus J ^a,b,c   Bobes Bascaran, Maria T ^b,c,d   Conejero Goldberg, Concepcion ^c   Davies, Peter ^c,e   Goldberg, Terry E ^c,e  

^a Benito Menni Complex Assistencial en Salut Mental   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; DISEASE MARKER; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL ASSESSMENT INVENTORY; HUMAN; ILLNESS TRAJECTORY; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; QUESTIONNAIRE; RISK; RISK FACTOR; TEMPORAL CORTEX; TEMPORAL LOBE; VERBAL MEMORY;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 80052538654     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.96     Document Type: Article

References (36)

1. Nestor P.J., Scheltens P., Hodges J.R. Advances in the early detection of Alzheimer's disease. Nat Med. 2004;10(suppl):S34-S41. (Pubitemid 38901865)
2. Hampel H., Broich K., Hoessler Y., Pantel J. Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci. 2009;11(2):141-157.
3. Shaw L.M., Korecka M., Clark C.M., Lee V.M., Trojanowski J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6(4):295-303. (Pubitemid 46505880)
4. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916-922.
5. Schmand B., Huizenga H.M., Van Gool W.A. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med. 2010;40 (1):135-145.
6. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006;5(3):228- 234.
7. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., Van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosén E., Aarsland D., Visser P.J., Schröder J., Marcusson J., De Leon M., Hampel H., Scheltens P., Pirttilä T., Wallin A., Jönhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385- 393.
8. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q.; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413.
9. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R. Jr, Weiner M.W.; Alzheimer's Disease Neuroimaging Initiative. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(pt 4):1067-1077.
10. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., Rusinek H., Pelton G.H., Honig L.S., Mayeux R., Stern Y., Tabert M.H., De Leon M.J. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology. 2007;68(11):828-836. (Pubitemid 46568534)
11. Whitwell J.L., Shiung M.M., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. Jr. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology. 2008;70(7):512-520. (Pubitemid 351653375)
12. Risacher S.L., Saykin A.J., West J.D., Shen L., Firpi H.A., McDonald B.C.; Alzheimer's Disease Neuroimaging Initiative (ADNI). Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res. 2009;6(4): 347-361.
13. Querbes O., Aubry F., Pariente J., Lotterie J.A., Deaposmonet J.F., Duret V., Puel M., Berry I., Fort J.C., Celsis P.; Alzheimer's Disease Neuroimaging Initiative. Early diagnosis of Alzheimer's disease using cortical thickness: Impact of cognitive reserve. Brain. 2009;132(pt 8):2036-2047.
14. Aggarwal N.T., Wilson R.S., Beck T.L., Bienias J.L., Bennett D.A. Mild cognitive impairment in different functional domains and incident Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76(11):1479-1484. (Pubitemid 41531689)
15. Jacobs D.M., Sano M., Dooneief G., Marder K., Bell K.L., Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology. 1995;45(5):957-962.
16. Dickerson B.C., Sperling R.A., Hyman B.T., Albert M.S., Blacker D. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry. 2007;64(12):1443-1450. (Pubitemid 350223563)
17. Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Nores A., Nadon G., Dunn E., St George-Hyslop P.H. Prediction of probable Alzheimer's disease in memoryimpaired patients: A prospective longitudinal study. Neurology. 1996;46(3): 661-665. (Pubitemid 26099629)
18. Blacker D., Lee H., Muzikansky A., Martin E.C., Tanzi R., McArdle J.J., Moss M., Albert M. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol. 2007;64(6):862-871. (Pubitemid 46919842)
19. Devanand D.P., Liu X., Tabert M.H., Pradhaban G., Cuasay K., Bell K., De Leon M.J., Doty R.L., Stern Y., Pelton G.H. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry. 2008;64(10):871-879.
20. Tabert M.H., Manly J.J., Liu X., Pelton G.H., Rosenblum S., Jacobs M., Zamora D., Goodkind M., Bell K., Stern Y., Devanand D.P. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry. 2006;63(8):916-924. (Pubitemid 44188484)
21. Goldberg T.E., Koppel J., Keehlisen L., Christen E., Dreses-Werringloer U., Conejero- Goldberg C, Gordon ML, Davies P. Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry. 2010;167(7):845- 853.
22. Alzheimer Research Forum. AlzGene. http://www.alzforum.org/. Accessed July 1, 2011.
23. Conejero-Goldberg C, Hyde TM, Chen S, Dreses-Werringloer U, Herman MM, Kleinman JE, Davies P, Goldberg TE. Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype [published online ahead of print May 18, 2009]. Mol Psychiatry. 2010. doi:10.1038/mp.2010.57.
24. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63(3):287-303.
25. Modrego P.J. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res. 2006;3(2): 161-170.
26. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015-2028.
27. Fleisher A.S., Sowell B.B., Taylor C., Gamst A.C., Petersen R.C., Thal L.J.; Alzheimer's Disease Cooperative Study. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68(19):1588-1595. (Pubitemid 46717983)
28. Jack C.R. Jr, Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397-1403. (Pubitemid 29190530)
29. Petersen R.C., Aisen P.S., Beckett L.A., et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization Neurology. 2010;74(3):201-209.
30. Walhovd K.B., Fjell A.M., Brewer J., McEvoy L.K., Fennema-Notestine C., Hagler D.J. Jr, Jennings R.G., Karow D., Dale A.M.; Alzheimer's Disease Neuroimaging Initiative. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol. 2010;31(2):347-354.
31. Gonen M. Analyzing Receiver Operating Characteristic Curves With SAS. Cary, NC: SAS Institute; 2007.
32. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. Jr; Alzheimer's Disease Neuroimaging Initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology. 2009;73(4):294-301.
33. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R. Jr, Weiner M.W., Jagust W.J.; Alzheimer's Disease Neuroimaging Initiative. Comparing predictors of conversion and decline in mild cognitive impairment [published online ahead of print]. Neurology. 2010;75(3):230-238.
34. Jack C.R. Jr, Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
35. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Brewer J.B., Dale A.M.; Alzheimer's Disease Neuroimaging Initiative. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci. 2010;30(6):2088-2101.
36. Ewers M., Walsh C., Trojanowski J.Q., Shaw L.M., Petersen R.C., Jack C.R. Jr, Feldman H.H., Bokde A.L., Alexander G.E., Scheltens P., Vellas B., Dubois B., Weiner M., Hampel H.; North American Alzheimer's Disease Neuroimaging Initiative (ADNI). Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance [published online ahead of print]. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2010.10.019.